Tags

Type your tag names separated by a space and hit enter

Using Serum Advanced Glycation End Products-Peptides to Improve the Efficacy of World Health Organization Fasting Plasma Glucose Criterion in Screening for Diabetes in High-Risk Chinese Subjects.
PLoS One. 2015; 10(9):e0137756.Plos

Abstract

The efficacy of using fasting plasma glucose (FPG) alone as a preferred screening test for diabetes has been questioned. This study was aimed to evaluate whether the use of serum advanced glycation end products-peptides (sAGEP) would help to improve the efficacy of FPG in diabetes screening among high-risk Chinese subjects with FPG <7.0 mmol/L. FPG, 2-h plasma glucose (2h-PG), serum glycated haemoglobin A1c (HbA1c), and sAGEP were measured in 857 Chinese subjects with risk factors for diabetes. The areas under receiver operating characteristic (ROC) curves generated by logistic regression models were assessed and compared to find the best model for diabetes screening in subjects with FPG <7.0 mmol/L. The optimal critical line was determined by maximizing the sum of sensitivity and specificity. Among the enrolled subjects, 730 of them had FPG <7.0 mmol/L, and only 41.7% new diabetes cases were identified using the 1999 World Health Organization FPG criterion (FPG ≥7.0 mmol/L). The area under ROC curves generated by the model on FPG-sAGEP was the largest compared with that on FPG-HbA1c, sAGEP, HbA1c or FPG in subjects with FPG <7.0 mmol/L. By maximizing the sum of sensitivity and specificity, the optimal critical line was determined as 0.69×FPG + 0.14×sAGEP = 7.03, giving a critical sensitivity of 91.2% in detecting 2h-PG ≥11.1 mmol/L, which was significantly higher than that of FPG-HbA1c or HbA1c. The model on FPG-sAGEP improves the efficacy of using FPG alone in detecting diabetes among high-risk Chinese subjects with FPG <7.0 mmol/L, and is worth being promoted for future diabetes screening.

Authors+Show Affiliations

Department of Endocrinology, Zhongda Hospital, Southeast University, Nanjing, P.R. China; Institute of Diabetes, School of Medicine, Southeast University, Nanjing, P.R. China.Department of Endocrinology, Zhongda Hospital, Southeast University, Nanjing, P.R. China; Institute of Diabetes, School of Medicine, Southeast University, Nanjing, P.R. China.Department of Endocrinology, Zhongda Hospital, Southeast University, Nanjing, P.R. China; Institute of Diabetes, School of Medicine, Southeast University, Nanjing, P.R. China.Department of Endocrinology, Zhongda Hospital, Southeast University, Nanjing, P.R. China; Institute of Diabetes, School of Medicine, Southeast University, Nanjing, P.R. China.Department of Endocrinology, Zhongda Hospital, Southeast University, Nanjing, P.R. China; Institute of Diabetes, School of Medicine, Southeast University, Nanjing, P.R. China.Department of Endocrinology, Zhongda Hospital, Southeast University, Nanjing, P.R. China.Institute of Diabetes, School of Medicine, Southeast University, Nanjing, P.R. China.Department of Endocrinology, Zhongda Hospital, Southeast University, Nanjing, P.R. China; Institute of Diabetes, School of Medicine, Southeast University, Nanjing, P.R. China.Department of Endocrinology, Zhongda Hospital, Southeast University, Nanjing, P.R. China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26368827

Citation

Sun, Zilin, et al. "Using Serum Advanced Glycation End Products-Peptides to Improve the Efficacy of World Health Organization Fasting Plasma Glucose Criterion in Screening for Diabetes in High-Risk Chinese Subjects." PloS One, vol. 10, no. 9, 2015, pp. e0137756.
Sun Z, He J, Qiu S, et al. Using Serum Advanced Glycation End Products-Peptides to Improve the Efficacy of World Health Organization Fasting Plasma Glucose Criterion in Screening for Diabetes in High-Risk Chinese Subjects. PLoS One. 2015;10(9):e0137756.
Sun, Z., He, J., Qiu, S., Lei, C., Zhou, Y., Xie, Z., Zhang, L., Wang, Y., & Jin, H. (2015). Using Serum Advanced Glycation End Products-Peptides to Improve the Efficacy of World Health Organization Fasting Plasma Glucose Criterion in Screening for Diabetes in High-Risk Chinese Subjects. PloS One, 10(9), e0137756. https://doi.org/10.1371/journal.pone.0137756
Sun Z, et al. Using Serum Advanced Glycation End Products-Peptides to Improve the Efficacy of World Health Organization Fasting Plasma Glucose Criterion in Screening for Diabetes in High-Risk Chinese Subjects. PLoS One. 2015;10(9):e0137756. PubMed PMID: 26368827.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Using Serum Advanced Glycation End Products-Peptides to Improve the Efficacy of World Health Organization Fasting Plasma Glucose Criterion in Screening for Diabetes in High-Risk Chinese Subjects. AU - Sun,Zilin, AU - He,Jiajia, AU - Qiu,Shanhu, AU - Lei,Chenghao, AU - Zhou,Yi, AU - Xie,Zuolin, AU - Zhang,Lin, AU - Wang,Yanping, AU - Jin,Hui, Y1 - 2015/09/14/ PY - 2015/04/08/received PY - 2015/08/20/accepted PY - 2015/9/15/entrez PY - 2015/9/15/pubmed PY - 2016/6/9/medline SP - e0137756 EP - e0137756 JF - PloS one JO - PLoS One VL - 10 IS - 9 N2 - The efficacy of using fasting plasma glucose (FPG) alone as a preferred screening test for diabetes has been questioned. This study was aimed to evaluate whether the use of serum advanced glycation end products-peptides (sAGEP) would help to improve the efficacy of FPG in diabetes screening among high-risk Chinese subjects with FPG <7.0 mmol/L. FPG, 2-h plasma glucose (2h-PG), serum glycated haemoglobin A1c (HbA1c), and sAGEP were measured in 857 Chinese subjects with risk factors for diabetes. The areas under receiver operating characteristic (ROC) curves generated by logistic regression models were assessed and compared to find the best model for diabetes screening in subjects with FPG <7.0 mmol/L. The optimal critical line was determined by maximizing the sum of sensitivity and specificity. Among the enrolled subjects, 730 of them had FPG <7.0 mmol/L, and only 41.7% new diabetes cases were identified using the 1999 World Health Organization FPG criterion (FPG ≥7.0 mmol/L). The area under ROC curves generated by the model on FPG-sAGEP was the largest compared with that on FPG-HbA1c, sAGEP, HbA1c or FPG in subjects with FPG <7.0 mmol/L. By maximizing the sum of sensitivity and specificity, the optimal critical line was determined as 0.69×FPG + 0.14×sAGEP = 7.03, giving a critical sensitivity of 91.2% in detecting 2h-PG ≥11.1 mmol/L, which was significantly higher than that of FPG-HbA1c or HbA1c. The model on FPG-sAGEP improves the efficacy of using FPG alone in detecting diabetes among high-risk Chinese subjects with FPG <7.0 mmol/L, and is worth being promoted for future diabetes screening. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/26368827/Using_Serum_Advanced_Glycation_End_Products_Peptides_to_Improve_the_Efficacy_of_World_Health_Organization_Fasting_Plasma_Glucose_Criterion_in_Screening_for_Diabetes_in_High_Risk_Chinese_Subjects_ L2 - https://dx.plos.org/10.1371/journal.pone.0137756 DB - PRIME DP - Unbound Medicine ER -